Patrys（PAB）株式概要Patrys Limitedはその子会社とともに、オーストラリアで癌治療のための抗体技術を開発・商業化している。 詳細PAB ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析収益が 100 万ドル未満 ( A$100K )過去1年間で株主の希薄化は大幅に進んだ 意味のある時価総額がありません ( A$30M )すべてのリスクチェックを見るPAB Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueAU$Current PriceAU$0.04739.1k% 割高 内在価値ディスカウントEst. Revenue$PastFuture-7m4m2016201920222025202620282031Revenue AU$42.3kEarnings AU$7.8kAdvancedSet Fair ValueView all narrativesPatrys Limited 競合他社ImugeneSymbol: ASX:IMUMarket cap: AU$45.7mNeuroScientific BiopharmaceuticalsSymbol: ASX:NSBMarket cap: AU$21.3mOptheaSymbol: ASX:OPTMarket cap: AU$19.2mParadigm BiopharmaceuticalsSymbol: ASX:PARMarket cap: AU$89.3m価格と性能株価の高値、安値、推移の概要Patrys過去の株価現在の株価AU$0.04752週高値AU$0.05152週安値AU$0.012ベータ1.071ヶ月の変化27.03%3ヶ月変化67.86%1年変化292.09%3年間の変化-64.39%5年間の変化-93.01%IPOからの変化-89.12%最新ニュースお知らせ • Jun 09Patrys Limited has filed a Follow-on Equity Offering in the amount of AUD 0.05 million.Patrys Limited has filed a Follow-on Equity Offering in the amount of AUD 0.05 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,083,333 Price\Range: AUD 0.024 Transaction Features: Subsequent Direct ListingBoard Change • May 20Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Anton Uvarov is the most experienced director on the board, commencing their role in 2025. Independent Non-Executive Chairman Peter Christie was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • May 01Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Anton Uvarov is the most experienced director on the board, commencing their role in 2025. Independent Non-Executive Chairman Peter Christie was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Apr 21Patrys Limited has completed a Follow-on Equity Offering in the amount of AUD 3.36 million.Patrys Limited has completed a Follow-on Equity Offering in the amount of AUD 3.36 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,666,667 Price\Range: AUD 0.024 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 133,333,333 Price\Range: AUD 0.024 Transaction Features: Subsequent Direct Listingお知らせ • Jan 29Patrys Limited (ASX:PAB) completed the acquisition of Reliis Ltd.Patrys Limited (ASX:PAB) entered into a binding agreement to acquire Reliis Ltd on November 26, 2025. The consideration consists of 110 million common equity of Patrys Limited to be issued for common equity and 25 million common equity of Patrys Limited to be issued for convertible debt of Reliis Ltd. Patrys Limited will pay an earnout payment 40 million Class A Performance Rights and 30 million Class B Performance Rights contingent upon the first subject being dosed in a Phase 1 Clinical Study and successful IND approval by a regulatory body, respectively. The transaction is subject to approval by regulatory board / committee and approval of offer by shareholders of Patrys Limited. As of January 19, 2026 acquirer shareholders have approved this transaction. Patrys Limited (ASX:PAB) completed the acquisition of Reliis Ltd on January 28, 2026. As of January 27, 2026 legal, technical and financial due diligence, all remaining conditions precedent under the Share Sale Agreement have been satisfied (or waived) and all transaction documents have now been duly executed.お知らせ • Nov 27Patrys Limited (ASX:PAB) entered into a binding agreement to acquire Reliis Ltd.Patrys Limited (ASX:PAB) entered into a binding agreement to acquire Reliis Ltd on November 26, 2025. The consideration consists of 110 million common equity of Patrys Limited to be issued for common equity and 25 million common equity of Patrys Limited to be issued for convertible debt of Reliis Ltd. Patrys Limited will pay an earnout payment 40 million Class A Performance Rights and 30 million Class B Performance Rights contingent upon the first subject being dosed in a Phase 1 Clinical Study and successful IND approval by a regulatory body, respectively. The transaction is subject to approval by regulatory board / committee and approval of offer by shareholders of Patrys Limited.最新情報をもっと見るRecent updatesお知らせ • Jun 09Patrys Limited has filed a Follow-on Equity Offering in the amount of AUD 0.05 million.Patrys Limited has filed a Follow-on Equity Offering in the amount of AUD 0.05 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,083,333 Price\Range: AUD 0.024 Transaction Features: Subsequent Direct ListingBoard Change • May 20Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Anton Uvarov is the most experienced director on the board, commencing their role in 2025. Independent Non-Executive Chairman Peter Christie was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • May 01Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Anton Uvarov is the most experienced director on the board, commencing their role in 2025. Independent Non-Executive Chairman Peter Christie was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Apr 21Patrys Limited has completed a Follow-on Equity Offering in the amount of AUD 3.36 million.Patrys Limited has completed a Follow-on Equity Offering in the amount of AUD 3.36 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,666,667 Price\Range: AUD 0.024 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 133,333,333 Price\Range: AUD 0.024 Transaction Features: Subsequent Direct Listingお知らせ • Jan 29Patrys Limited (ASX:PAB) completed the acquisition of Reliis Ltd.Patrys Limited (ASX:PAB) entered into a binding agreement to acquire Reliis Ltd on November 26, 2025. The consideration consists of 110 million common equity of Patrys Limited to be issued for common equity and 25 million common equity of Patrys Limited to be issued for convertible debt of Reliis Ltd. Patrys Limited will pay an earnout payment 40 million Class A Performance Rights and 30 million Class B Performance Rights contingent upon the first subject being dosed in a Phase 1 Clinical Study and successful IND approval by a regulatory body, respectively. The transaction is subject to approval by regulatory board / committee and approval of offer by shareholders of Patrys Limited. As of January 19, 2026 acquirer shareholders have approved this transaction. Patrys Limited (ASX:PAB) completed the acquisition of Reliis Ltd on January 28, 2026. As of January 27, 2026 legal, technical and financial due diligence, all remaining conditions precedent under the Share Sale Agreement have been satisfied (or waived) and all transaction documents have now been duly executed.お知らせ • Nov 27Patrys Limited (ASX:PAB) entered into a binding agreement to acquire Reliis Ltd.Patrys Limited (ASX:PAB) entered into a binding agreement to acquire Reliis Ltd on November 26, 2025. The consideration consists of 110 million common equity of Patrys Limited to be issued for common equity and 25 million common equity of Patrys Limited to be issued for convertible debt of Reliis Ltd. Patrys Limited will pay an earnout payment 40 million Class A Performance Rights and 30 million Class B Performance Rights contingent upon the first subject being dosed in a Phase 1 Clinical Study and successful IND approval by a regulatory body, respectively. The transaction is subject to approval by regulatory board / committee and approval of offer by shareholders of Patrys Limited.お知らせ • Nov 11Patrys Limited Announces Management Changes, Effective 10 November 2025Patrys Limited announced that Dr. James Campbell has tendered his resignation as a Non-Executive Director of the Company, effective 10 November 2025. Dr. Campbell's tenure with the company commenced in November 2014, where he was originally a Non-Executive Director from 12 November 2014, then appointed as Managing Director and Chief Executive Officer (CEO) of the Company for the period 13 April 2015 to 30 June 2025. Dr. Campbell's CEO role was made redundant on 1 July 2025. Since 1 July 2025 Dr Campbell has been a Non-Executive Director. The company also announced the appointment of Mr. Brian Leedman as a Non-Executive Director, effective 10 November 2025. Mr. Brian Leedman is a seasoned biotechnology executive and company director with more than 20 years of experience in corporate strategy, investor relations, and capital markets within the life sciences sector. He is the founder and former director of ResApp Health Ltd, which was acquired by Pfizer Inc. in 2022, and has held board roles across a range of ASX-listed biotechnology companies, including Neuroscientific Biopharmaceuticals, Neurotech International, Alcidion Corporation, Oncosil and others. Mr. Leedman is currently a Non-Executive Chairman of Blinklab Ltd. and has extensive experience guiding emerging biomedical companies from early research through to clinical development and commercialisation. He is well recognised in the Australian biotech community for his leadership in capital raising, corporate governance, and building investor awareness for innovative medical technologies. Mr. Leedman holds a Bachelor of Economics and an MBA from the University of Western Australia. His deep understanding of the biotech industry and proven record of creating shareholder value will provide valuable strategic insight to Patrys as it advances its deoxymab platform through preclinical and clinical development. The Company also advises that Mr. Johnathon Busing and Mr. Kieran Witt have been appointed as Joint Company Secretaries of the Company, with effect from 10 November 2025. Mr. Busing is a Chartered Accountant and the founder of Eleven Corporate, a Perth-based corporate services firm. He has extensive experience in accounting, corporate advisory, governance and ASX compliance, and currently acts as Company Secretary and Chief Financial Officer for a number of ASX- listed companies. Mr. Witt is a Chartered Accountant with extensive experience as a consultant advising ASX listed companies on capital raisings, mergers and acquisitions, statutory accounting requirements and corporate compliance. Currently, he also serves as the Company Secretary for several other ASX-listed companies, where he oversees compliance with corporate governance requirements and regulatory obligations. He is a member of Chartered Accountants Australia and New Zealand and holds a Bachelor of Commerce (Accounting). Mr. Busing and Mr. Witt will be the persons responsible for communication with the ASX in relation to Listing Rule matters under Listing Rule 12.6. As part of this change, Mr. Stefan Ross will step down from his role as Company Secretary, effective 10 November 2025.お知らせ • Sep 08Patrys Limited, Annual General Meeting, Oct 09, 2025Patrys Limited, Annual General Meeting, Oct 09, 2025.Reported Earnings • Aug 31Full year 2025 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2024)Full year 2025 results: AU$0.001 loss per share (in line with FY 2024). Revenue: AU$828.5k (down 41% from FY 2024). Net loss: AU$3.01m (loss narrowed 15% from FY 2024). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings.Board Change • Aug 18No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Chairman Peter Christie was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jul 23Patrys Limited has filed a Follow-on Equity Offering in the amount of AUD 1.774357 million.Patrys Limited has filed a Follow-on Equity Offering in the amount of AUD 1.774357 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,774,357,402 Price\Range: AUD 0.001 Discount Per Security: AUD 0.00006 Transaction Features: Rights Offeringお知らせ • Jun 10Patrys Limited has completed a Follow-on Equity Offering in the amount of AUD 0.358363 million.Patrys Limited has completed a Follow-on Equity Offering in the amount of AUD 0.358363 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 308,362,535 Price\Range: AUD 0.001 Discount Per Security: AUD 0.00006 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 50,000,000 Price\Range: AUD 0.001 Security Features: Attached Options Transaction Features: Subsequent Direct ListingBoard Change • Feb 04No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Chairman of the Board Charmaine Gittleson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Dec 31No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Chairman of the Board Charmaine Gittleson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Oct 21Patrys Limited, Annual General Meeting, Nov 22, 2024Patrys Limited, Annual General Meeting, Nov 22, 2024.New Risk • Aug 24New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$1.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$1.8m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 19% per year over the past 5 years. Revenue is less than US$1m (AU$1.4m revenue, or US$948k). Market cap is less than US$10m (AU$12.3m market cap, or US$8.38m).New Risk • Jul 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 32% per year over the past 5 years. Minor Risks Revenue is less than US$5m (AU$1.7m revenue, or US$1.1m). Market cap is less than US$100m (AU$16.4m market cap, or US$11.0m).New Risk • May 16New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$14.4m (US$9.61m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 32% per year over the past 5 years. Market cap is less than US$10m (AU$14.4m market cap, or US$9.61m). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (AU$1.7m revenue, or US$1.1m).New Risk • Feb 09New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$14.4m (US$9.38m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$5.8m free cash flow). Earnings have declined by 36% per year over the past 5 years. Market cap is less than US$10m (AU$14.4m market cap, or US$9.38m). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Revenue is less than US$5m (AU$2.9m revenue, or US$1.9m).New Risk • Nov 27New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$14.4m (US$9.51m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$5.8m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 36% per year over the past 5 years. Market cap is less than US$10m (AU$14.4m market cap, or US$9.51m). Minor Risk Revenue is less than US$5m (AU$2.9m revenue, or US$1.9m).お知らせ • Sep 15Patrys Limited Announces Retirement of Suzy Jones as DirectorPatrys Limited announced that Ms. Suzy Jones will be retiring as a Director of the company effective from close of business on 15 September 2023. Ms. Jones joined the Patrys Board in 2011 and has played a pivotal role in the Company's evolution over the last decade. Her corporate strategy, drug development and business development guidance helped Patrys gain access to novel technologies and expand its portfolio. Ms Jones also leveraged her global network to attract industry experts to support Patrys' mission. Ms. Jones is Founder and Managing Partner of DNA Ink LLC, a life sciences advisory firm in San Francisco and prior to starting her own firm, spent 20 years at Genentech where she served in roles in immunology research, product development and business development. Ms. Jones' departure aligns with the Company's previously noted vision to refresh its Board of Directors in keeping with good governance practices. Ms. Jones has on-going obligations as co-founder of an antibody drug conjugate company and consultant CBO to her DNA Ink clients. Patrys has now commenced searching for a new Non-Executive Director to help contribute to its next phase of growth as it becomes a clinical-stage therapeutic development company.Reported Earnings • Aug 30Full year 2023 earnings released: AU$0.003 loss per share (vs AU$0.003 loss in FY 2022)Full year 2023 results: AU$0.003 loss per share (in line with FY 2022). Revenue: AU$2.85m (down 14% from FY 2022). Net loss: AU$7.06m (loss widened 4.1% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 9% per year.お知らせ • Aug 28Patrys Limited, Annual General Meeting, Nov 15, 2023Patrys Limited, Annual General Meeting, Nov 15, 2023.New Risk • Aug 27New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$6.9m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 36% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Revenue is less than US$5m (AU$3.5m revenue, or US$2.2m). Market cap is less than US$100m (AU$18.5m market cap, or US$11.9m).New Risk • Jul 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$6.9m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 36% per year over the past 5 years. Minor Risks Revenue is less than US$5m (AU$3.5m revenue, or US$2.4m). Market cap is less than US$100m (AU$22.6m market cap, or US$15.5m).Reported Earnings • Feb 25First half 2023 earnings released: AU$0.002 loss per share (vs AU$0.002 loss in 1H 2022)First half 2023 results: AU$0.002 loss per share (in line with 1H 2022). Revenue: AU$1.83m (up 10% from 1H 2022). Net loss: AU$3.89m (loss narrowed 14% from 1H 2022). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings.Board Change • Nov 17No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Chairman Charmaine Gittleson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 31Full year 2022 earnings released: AU$0.003 loss per share (vs AU$0.003 loss in FY 2021)Full year 2022 results: AU$0.003 loss per share (vs AU$0.003 loss in FY 2021). Revenue: AU$3.33m (up 149% from FY 2021). Net loss: AU$6.78m (loss widened 67% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Member of Scientific Advisory Board Peter Ordentlich was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 27Full year 2021 earnings released: AU$0.003 loss per share (vs AU$0.003 loss in FY 2020)The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2021 results: Revenue: AU$1.34m (up 73% from FY 2020). Net loss: AU$4.06m (loss widened 48% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.Reported Earnings • Feb 21First half 2021 earnings released: AU$0.001 loss per share (vs AU$0.002 loss in 1H 2020)First half 2021 results: Net loss: AU$2.00m (loss widened 17% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.株主還元PABAU BiotechsAU 市場7D9.3%5.7%-1.4%1Y292.1%-49.7%2.2%株主還元を見る業界別リターン: PAB過去 1 年間で-49.7 % の収益を上げたAustralian Biotechs業界を上回りました。リターン対市場: PAB過去 1 年間で2.2 % の収益を上げたAustralian市場を上回りました。価格変動Is PAB's price volatile compared to industry and market?PAB volatilityPAB Average Weekly Movement11.4%Biotechs Industry Average Movement10.6%Market Average Movement10.1%10% most volatile stocks in AU Market17.3%10% least volatile stocks in AU Market4.0%安定した株価: PAB 、 Australian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: PABの 週次ボラティリティ は、過去 1 年間で40%から11%に減少しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト2006n/aSam Southpatrys.comPatrys社は、その子会社とともに、オーストラリアで癌治療のための抗体技術を開発・商業化している。同社はPAT-DX1とも呼ばれるデオキシマブ3E10を開発し、原発性および二次性脳腫瘍、NETosisを伴う転移巣の治療、あるいは放射線や多くの化学療法薬などのDNA損傷剤との併用に使用している。さらに、PAT-DX1のDNA標的特性を持ちながら、組織分布、薬物動態プロファイルなどの薬学的特性が異なるフルサイズ抗体であるPAT-DX3の開発も行っている。さらに、DNAターゲティング、血液脳関門、NETosis阻害ヒト治療への応用にも関与しています。パトライスは2006年に設立され、オーストラリアのメルボルンに本社を置いています。もっと見るPatrys Limited 基礎のまとめPatrys の収益と売上を時価総額と比較するとどうか。PAB 基礎統計学時価総額AU$30.00m収益（TTM）-AU$4.51m売上高(TTM)AU$100.38k298.8xP/Sレシオ-6.6xPER（株価収益率PAB は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計PAB 損益計算書（TTM）収益AU$100.38k売上原価AU$0売上総利益AU$100.38kその他の費用AU$4.61m収益-AU$4.51m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.0068グロス・マージン100.00%純利益率-4,497.20%有利子負債／自己資本比率0%PAB の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/21 17:58終値2026/06/19 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Patrys Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Matthijs SmithLodge Partners Pty Ltd.
お知らせ • Jun 09Patrys Limited has filed a Follow-on Equity Offering in the amount of AUD 0.05 million.Patrys Limited has filed a Follow-on Equity Offering in the amount of AUD 0.05 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,083,333 Price\Range: AUD 0.024 Transaction Features: Subsequent Direct Listing
Board Change • May 20Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Anton Uvarov is the most experienced director on the board, commencing their role in 2025. Independent Non-Executive Chairman Peter Christie was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • May 01Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Anton Uvarov is the most experienced director on the board, commencing their role in 2025. Independent Non-Executive Chairman Peter Christie was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Apr 21Patrys Limited has completed a Follow-on Equity Offering in the amount of AUD 3.36 million.Patrys Limited has completed a Follow-on Equity Offering in the amount of AUD 3.36 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,666,667 Price\Range: AUD 0.024 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 133,333,333 Price\Range: AUD 0.024 Transaction Features: Subsequent Direct Listing
お知らせ • Jan 29Patrys Limited (ASX:PAB) completed the acquisition of Reliis Ltd.Patrys Limited (ASX:PAB) entered into a binding agreement to acquire Reliis Ltd on November 26, 2025. The consideration consists of 110 million common equity of Patrys Limited to be issued for common equity and 25 million common equity of Patrys Limited to be issued for convertible debt of Reliis Ltd. Patrys Limited will pay an earnout payment 40 million Class A Performance Rights and 30 million Class B Performance Rights contingent upon the first subject being dosed in a Phase 1 Clinical Study and successful IND approval by a regulatory body, respectively. The transaction is subject to approval by regulatory board / committee and approval of offer by shareholders of Patrys Limited. As of January 19, 2026 acquirer shareholders have approved this transaction. Patrys Limited (ASX:PAB) completed the acquisition of Reliis Ltd on January 28, 2026. As of January 27, 2026 legal, technical and financial due diligence, all remaining conditions precedent under the Share Sale Agreement have been satisfied (or waived) and all transaction documents have now been duly executed.
お知らせ • Nov 27Patrys Limited (ASX:PAB) entered into a binding agreement to acquire Reliis Ltd.Patrys Limited (ASX:PAB) entered into a binding agreement to acquire Reliis Ltd on November 26, 2025. The consideration consists of 110 million common equity of Patrys Limited to be issued for common equity and 25 million common equity of Patrys Limited to be issued for convertible debt of Reliis Ltd. Patrys Limited will pay an earnout payment 40 million Class A Performance Rights and 30 million Class B Performance Rights contingent upon the first subject being dosed in a Phase 1 Clinical Study and successful IND approval by a regulatory body, respectively. The transaction is subject to approval by regulatory board / committee and approval of offer by shareholders of Patrys Limited.
お知らせ • Jun 09Patrys Limited has filed a Follow-on Equity Offering in the amount of AUD 0.05 million.Patrys Limited has filed a Follow-on Equity Offering in the amount of AUD 0.05 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,083,333 Price\Range: AUD 0.024 Transaction Features: Subsequent Direct Listing
Board Change • May 20Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Anton Uvarov is the most experienced director on the board, commencing their role in 2025. Independent Non-Executive Chairman Peter Christie was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • May 01Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Anton Uvarov is the most experienced director on the board, commencing their role in 2025. Independent Non-Executive Chairman Peter Christie was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Apr 21Patrys Limited has completed a Follow-on Equity Offering in the amount of AUD 3.36 million.Patrys Limited has completed a Follow-on Equity Offering in the amount of AUD 3.36 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,666,667 Price\Range: AUD 0.024 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 133,333,333 Price\Range: AUD 0.024 Transaction Features: Subsequent Direct Listing
お知らせ • Jan 29Patrys Limited (ASX:PAB) completed the acquisition of Reliis Ltd.Patrys Limited (ASX:PAB) entered into a binding agreement to acquire Reliis Ltd on November 26, 2025. The consideration consists of 110 million common equity of Patrys Limited to be issued for common equity and 25 million common equity of Patrys Limited to be issued for convertible debt of Reliis Ltd. Patrys Limited will pay an earnout payment 40 million Class A Performance Rights and 30 million Class B Performance Rights contingent upon the first subject being dosed in a Phase 1 Clinical Study and successful IND approval by a regulatory body, respectively. The transaction is subject to approval by regulatory board / committee and approval of offer by shareholders of Patrys Limited. As of January 19, 2026 acquirer shareholders have approved this transaction. Patrys Limited (ASX:PAB) completed the acquisition of Reliis Ltd on January 28, 2026. As of January 27, 2026 legal, technical and financial due diligence, all remaining conditions precedent under the Share Sale Agreement have been satisfied (or waived) and all transaction documents have now been duly executed.
お知らせ • Nov 27Patrys Limited (ASX:PAB) entered into a binding agreement to acquire Reliis Ltd.Patrys Limited (ASX:PAB) entered into a binding agreement to acquire Reliis Ltd on November 26, 2025. The consideration consists of 110 million common equity of Patrys Limited to be issued for common equity and 25 million common equity of Patrys Limited to be issued for convertible debt of Reliis Ltd. Patrys Limited will pay an earnout payment 40 million Class A Performance Rights and 30 million Class B Performance Rights contingent upon the first subject being dosed in a Phase 1 Clinical Study and successful IND approval by a regulatory body, respectively. The transaction is subject to approval by regulatory board / committee and approval of offer by shareholders of Patrys Limited.
お知らせ • Nov 11Patrys Limited Announces Management Changes, Effective 10 November 2025Patrys Limited announced that Dr. James Campbell has tendered his resignation as a Non-Executive Director of the Company, effective 10 November 2025. Dr. Campbell's tenure with the company commenced in November 2014, where he was originally a Non-Executive Director from 12 November 2014, then appointed as Managing Director and Chief Executive Officer (CEO) of the Company for the period 13 April 2015 to 30 June 2025. Dr. Campbell's CEO role was made redundant on 1 July 2025. Since 1 July 2025 Dr Campbell has been a Non-Executive Director. The company also announced the appointment of Mr. Brian Leedman as a Non-Executive Director, effective 10 November 2025. Mr. Brian Leedman is a seasoned biotechnology executive and company director with more than 20 years of experience in corporate strategy, investor relations, and capital markets within the life sciences sector. He is the founder and former director of ResApp Health Ltd, which was acquired by Pfizer Inc. in 2022, and has held board roles across a range of ASX-listed biotechnology companies, including Neuroscientific Biopharmaceuticals, Neurotech International, Alcidion Corporation, Oncosil and others. Mr. Leedman is currently a Non-Executive Chairman of Blinklab Ltd. and has extensive experience guiding emerging biomedical companies from early research through to clinical development and commercialisation. He is well recognised in the Australian biotech community for his leadership in capital raising, corporate governance, and building investor awareness for innovative medical technologies. Mr. Leedman holds a Bachelor of Economics and an MBA from the University of Western Australia. His deep understanding of the biotech industry and proven record of creating shareholder value will provide valuable strategic insight to Patrys as it advances its deoxymab platform through preclinical and clinical development. The Company also advises that Mr. Johnathon Busing and Mr. Kieran Witt have been appointed as Joint Company Secretaries of the Company, with effect from 10 November 2025. Mr. Busing is a Chartered Accountant and the founder of Eleven Corporate, a Perth-based corporate services firm. He has extensive experience in accounting, corporate advisory, governance and ASX compliance, and currently acts as Company Secretary and Chief Financial Officer for a number of ASX- listed companies. Mr. Witt is a Chartered Accountant with extensive experience as a consultant advising ASX listed companies on capital raisings, mergers and acquisitions, statutory accounting requirements and corporate compliance. Currently, he also serves as the Company Secretary for several other ASX-listed companies, where he oversees compliance with corporate governance requirements and regulatory obligations. He is a member of Chartered Accountants Australia and New Zealand and holds a Bachelor of Commerce (Accounting). Mr. Busing and Mr. Witt will be the persons responsible for communication with the ASX in relation to Listing Rule matters under Listing Rule 12.6. As part of this change, Mr. Stefan Ross will step down from his role as Company Secretary, effective 10 November 2025.
お知らせ • Sep 08Patrys Limited, Annual General Meeting, Oct 09, 2025Patrys Limited, Annual General Meeting, Oct 09, 2025.
Reported Earnings • Aug 31Full year 2025 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2024)Full year 2025 results: AU$0.001 loss per share (in line with FY 2024). Revenue: AU$828.5k (down 41% from FY 2024). Net loss: AU$3.01m (loss narrowed 15% from FY 2024). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings.
Board Change • Aug 18No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Chairman Peter Christie was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jul 23Patrys Limited has filed a Follow-on Equity Offering in the amount of AUD 1.774357 million.Patrys Limited has filed a Follow-on Equity Offering in the amount of AUD 1.774357 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,774,357,402 Price\Range: AUD 0.001 Discount Per Security: AUD 0.00006 Transaction Features: Rights Offering
お知らせ • Jun 10Patrys Limited has completed a Follow-on Equity Offering in the amount of AUD 0.358363 million.Patrys Limited has completed a Follow-on Equity Offering in the amount of AUD 0.358363 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 308,362,535 Price\Range: AUD 0.001 Discount Per Security: AUD 0.00006 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 50,000,000 Price\Range: AUD 0.001 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
Board Change • Feb 04No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Chairman of the Board Charmaine Gittleson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Dec 31No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Chairman of the Board Charmaine Gittleson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 21Patrys Limited, Annual General Meeting, Nov 22, 2024Patrys Limited, Annual General Meeting, Nov 22, 2024.
New Risk • Aug 24New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$1.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$1.8m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 19% per year over the past 5 years. Revenue is less than US$1m (AU$1.4m revenue, or US$948k). Market cap is less than US$10m (AU$12.3m market cap, or US$8.38m).
New Risk • Jul 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 32% per year over the past 5 years. Minor Risks Revenue is less than US$5m (AU$1.7m revenue, or US$1.1m). Market cap is less than US$100m (AU$16.4m market cap, or US$11.0m).
New Risk • May 16New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$14.4m (US$9.61m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 32% per year over the past 5 years. Market cap is less than US$10m (AU$14.4m market cap, or US$9.61m). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (AU$1.7m revenue, or US$1.1m).
New Risk • Feb 09New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$14.4m (US$9.38m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$5.8m free cash flow). Earnings have declined by 36% per year over the past 5 years. Market cap is less than US$10m (AU$14.4m market cap, or US$9.38m). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Revenue is less than US$5m (AU$2.9m revenue, or US$1.9m).
New Risk • Nov 27New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$14.4m (US$9.51m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$5.8m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 36% per year over the past 5 years. Market cap is less than US$10m (AU$14.4m market cap, or US$9.51m). Minor Risk Revenue is less than US$5m (AU$2.9m revenue, or US$1.9m).
お知らせ • Sep 15Patrys Limited Announces Retirement of Suzy Jones as DirectorPatrys Limited announced that Ms. Suzy Jones will be retiring as a Director of the company effective from close of business on 15 September 2023. Ms. Jones joined the Patrys Board in 2011 and has played a pivotal role in the Company's evolution over the last decade. Her corporate strategy, drug development and business development guidance helped Patrys gain access to novel technologies and expand its portfolio. Ms Jones also leveraged her global network to attract industry experts to support Patrys' mission. Ms. Jones is Founder and Managing Partner of DNA Ink LLC, a life sciences advisory firm in San Francisco and prior to starting her own firm, spent 20 years at Genentech where she served in roles in immunology research, product development and business development. Ms. Jones' departure aligns with the Company's previously noted vision to refresh its Board of Directors in keeping with good governance practices. Ms. Jones has on-going obligations as co-founder of an antibody drug conjugate company and consultant CBO to her DNA Ink clients. Patrys has now commenced searching for a new Non-Executive Director to help contribute to its next phase of growth as it becomes a clinical-stage therapeutic development company.
Reported Earnings • Aug 30Full year 2023 earnings released: AU$0.003 loss per share (vs AU$0.003 loss in FY 2022)Full year 2023 results: AU$0.003 loss per share (in line with FY 2022). Revenue: AU$2.85m (down 14% from FY 2022). Net loss: AU$7.06m (loss widened 4.1% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 9% per year.
お知らせ • Aug 28Patrys Limited, Annual General Meeting, Nov 15, 2023Patrys Limited, Annual General Meeting, Nov 15, 2023.
New Risk • Aug 27New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$6.9m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 36% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Revenue is less than US$5m (AU$3.5m revenue, or US$2.2m). Market cap is less than US$100m (AU$18.5m market cap, or US$11.9m).
New Risk • Jul 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$6.9m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 36% per year over the past 5 years. Minor Risks Revenue is less than US$5m (AU$3.5m revenue, or US$2.4m). Market cap is less than US$100m (AU$22.6m market cap, or US$15.5m).
Reported Earnings • Feb 25First half 2023 earnings released: AU$0.002 loss per share (vs AU$0.002 loss in 1H 2022)First half 2023 results: AU$0.002 loss per share (in line with 1H 2022). Revenue: AU$1.83m (up 10% from 1H 2022). Net loss: AU$3.89m (loss narrowed 14% from 1H 2022). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings.
Board Change • Nov 17No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Chairman Charmaine Gittleson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 31Full year 2022 earnings released: AU$0.003 loss per share (vs AU$0.003 loss in FY 2021)Full year 2022 results: AU$0.003 loss per share (vs AU$0.003 loss in FY 2021). Revenue: AU$3.33m (up 149% from FY 2021). Net loss: AU$6.78m (loss widened 67% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Member of Scientific Advisory Board Peter Ordentlich was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 27Full year 2021 earnings released: AU$0.003 loss per share (vs AU$0.003 loss in FY 2020)The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2021 results: Revenue: AU$1.34m (up 73% from FY 2020). Net loss: AU$4.06m (loss widened 48% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.
Reported Earnings • Feb 21First half 2021 earnings released: AU$0.001 loss per share (vs AU$0.002 loss in 1H 2020)First half 2021 results: Net loss: AU$2.00m (loss widened 17% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
